Bronchopulmonary Dysplasia Clinical Trial
Official title:
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
Verified date | August 2019 |
Source | Oregon Health and Science University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two additional weeks of CPAP and room air versus room air alone. We hypothesize that infants randomized to additional CPAP will demonstrate an increased functional residual capacity (at the end of the two week study period and prior to discharge) compared to those randomized to room air.
Status | Completed |
Enrollment | 50 |
Est. completion date | September 2017 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 1 Year |
Eligibility |
Inclusion Criteria: - Gestational age at birth <33 weeks - Required CPAP for a minimum of 24 hours for respiratory distress - Patient on CPAP and room air at time of randomization Exclusion Criteria: - Complex congenital heart disease other than patent ductus arteriosus or atrial septal defect - Major malformations or chromosomal anomalies - Multiple gestation greater than twins - Culture proven sepsis or unstable at time of randomization |
Country | Name | City | State |
---|---|---|---|
United States | Oregon Health & Science University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in the Growth Parameters Between the Randomized Premature Infants | Changes in growth parameters will be compared between randomized groups. | From randomization through discharge at about 35-37 weeks of corrected gestational age. | |
Other | The Number of Participants With Adverse Events and Serious Adverse Events in the Randomized Groups of Premature Infants. | Adverse events and serious adverse events occurring in the randomized groups will be documented carefully | From randomization through discharge from the neonatal intensive care unit (an average of 35 to 37 weeks of corrected gestational age). | |
Other | Corrected Gestational Age at Which Full Nipple Feeds Are Achieved | The corrected gestational age at which full nipple feeds are achieved will be compared between the randomized groups. | Randomization through discharge at about 35-37 weeks of corrected gestational age. | |
Other | Incidence of Wheezing Through One Year of Age | Incidence of wheezing will be compared through one year of corrected gestational age between the randomized groups. | Discharge through one year of corrected age | |
Other | Cost Comparison Between Randomized Groups | Cost comparison through 12 months of corrected gestational age between the randomized groups per percent improvement in FRC measured at discharge between the groups. | Through 12 months of corrected age | |
Other | Days on Oxygen Between the Randomized Groups | The days of oxygen supplementation will be compared between the groups of randomized patients. | Through discharge at about 35-37 weeks of corrected gestational age | |
Other | Days in the Hospital | The days in the hospital will be compared between the randomized groups. | Delivery through discharge at about 35-37 weeks of corrected gestational age | |
Primary | Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants | Functional residual capacity (FRC) was measured with the nitrogen washout technique. For the nitrogen washout technique, calibration is done with 2 known volumes, and a calibration line was constructed for the system at the specific flow rate and used to correlate the nitrogen washed out to the infant's FRC. The system corrected for dead space and corrected the FRC to body temperature, pressure, and water-saturated conditions. Acceptance criteria included: 1) infant supine and quietly asleep; 2) test initiated at end expiration; 3) no evidence of leak on tracing of the washout; 4) consistent tracings; 5) at least 2-3 measurements with a coefficient of variation <10%. These are testing and acceptance criteria outlined by the American Thoracic Society and European Respiratory Society. | Just prior to randomization, two weeks later and at discharge (an average of 34 to 37 weeks of corrected gestational age). | |
Secondary | Measurements of Passive Respiratory Compliance in Randomized Premature Infants | Measurements of passive respiratory compliance will be done with the single breath occlusion technique. | Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age | |
Secondary | Passive Respiratory Resistance in Randomized Premature Infants | Measurements of passive respiratory resistance will be done with the single breath occlusion technique. | Just prior to randomization, two weeks after randomization, and at discharge at about 35-37 weeks of corrected gestational age. | |
Secondary | Measurements of Tidal Flow Volume Loops Will be Done in the Randomized Premature Infants. | Characteristics of tidal flow volume loops will be measured. | Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A | |
Active, not recruiting |
NCT04662151 -
A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)
|
Phase 1 |